COMMUNIQUÉS West-GlobeNewswire

X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
22/09/2026
WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- X-Chem, a global leader in innovative drug discovery services, announced the achievement of a milestone following Relay Therapeutics’ initiation of a Phase 3 clinical [...]
Porch Light Health and CBHC Expand Access to Methadone Treatment in Northern Colorado
22/09/2026
New medication units in Fort Collins and Greeley bring methadone treatment into existing Porch Light Health outpatient addiction clinics DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- As drug overdose deaths continue to [...]
Eclipse Energy and Wood Validate Pathway to Low-Cost, Ultra-Low-Carbon Hydrogen from Depleted Oil Reservoirs
22/09/2026
RenovaStrata™ H2 achieves modeled LCOH as low as $0.56/kg and carbon intensity of 0.076 kgCO₂e/kgH₂, reinforcing potential for commercial-scale, ultra-low-carbon hydrogen HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- [...]
New Study Reveals When College Students at Risk for Suicide Begin to Improve in Virtual Therapy
22/09/2026
Peer-reviewed TimelyCare research published in DIGITAL HEALTH finds many students show early improvement while underscoring the need for continued suicide risk monitoring. Fort Worth, TX, Sept. 22, 2026 (GLOBE NEWSWIRE [...]
Ophirex Publishes Data from Phase 2 BRAVIO Trial Evaluating Intravenous Followed by Oral Varespladib for Snakebite
22/09/2026
Trial evaluated varespladib administered after antivenom across multiple snake species in India and the United States Clinically important signals of benefit observed in patients bitten by kraits and copperheads CORTE [...]
Seek Labs Launches Open Impact Program at Clinton Global Initiative to Advance Therapeutic Development for Neglected Infectious Diseases
22/09/2026
New Commitment to Action will apply Seek Labs’ BioSeeker AI and Sequence Ablation Therapeutics platform to diseases historically underserved by traditional therapeutic development SALT LAKE CITY, Sept. 22, 2026 (GLOBE [...]
Rendever Expands Dementia & Empathy Training With a New Mode for Family Caregivers
22/09/2026
New feature brings guidance from a family caregiver turned dementia researcher directly into the immersive training, helping families navigate a loved one's condition at home BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- [...]
Kylo Peptides Strengthens U.S.-Based Supply Chain for Research Peptides with Faster Domestic Fulfillment
22/09/2026
Sheridan, Wyoming, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ] has strengthened domestic fulfillment for research peptides, routing more order flow through one U.S. warehouse so [...]
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity
22/09/2026
Press release – No. 17 / 2026 Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity The Phase 3 initiation marks a defining step toward [...]
SK pharmteco et GEMMABio renforcent leur collaboration dans la fabrication de traitements pour les maladies rares après une étape clé de l’essai clinique consacré à l’amyotrophie spinale (SMA)
22/09/2026
L’administration du traitement au premier patient constitue une étape importante pour la communauté des personnes atteintes de SMA et témoigne du renforcement de la collaboration dans le domaine de la fabrication de [...]
Applied Biologics Announces Last Patient, Last Visit in CAMPX Randomized Controlled Trial of XWRAP®
22/09/2026
Completion of patient follow-up marks major clinical milestone as 222-patient diabetic foot ulcer study advances toward database lock and final analysis SCOTTSDALE, Ariz., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Applied [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 38 - 2026
22/09/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 14 septembre au 18 septembre 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2026
22/09/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 14th September to 18th September 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial [...]
Lymphatic Malformation Alliance (LMA) Meets with FDA Leadership to Elevate Awareness of Lymphatic Malformations and Advance the Urgent Need for Approved Treatments
22/09/2026
LMA brings patient and physician perspectives to FDA leadership to elevate awareness of lymphatic malformations Patient experience highlights the serious, lifelong burden and significant unmet need LMA calls for greater [...]
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
22/09/2026
Nes-Ziona, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the termination of a [...]
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
22/09/2026
-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) -- BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a [...]
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
22/09/2026
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic [...]
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
22/09/2026
Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential [...]
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
22/09/2026
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision [...]

Pages